Tradestie Institutional Equity Comparison Engine · Market Close Feb 11, 2026

GBIO vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–2 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: GBIO 1 – 3 AVDL (2 Tie) Matrix Metrics: GBIO 2 – 7 AVDL

As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GBIO carries a Unified Composite Score of 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GBIO vs AVDL
GBIO NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
$5.34
-6.97% 1D
Market Cap $38.7M
TTM Revenue $15M
Forward P/E 7.9x
Beta / 30D Vol 0.80β · 26% Vol
Unified Composite Score
58.8 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 53.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.7 · SMA20: $5.61 · SMA50: $5.49
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (GBIO 1 – 3 AVDL)

Columns: Metric · GBIO · AVDL
1. Valuation Multiples GBIO
Forward P/E 7.9x 28.8x
Trailing P/E 7.9x 16.8x
PEG Ratio N/M 0.07x
EV / Revenue 2.5x 8.5x
2. Growth & Scale AVDL
Revenue Growth (YoY) -78.9% +54.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $15M $249M
Market Cap $38.7M $2.1B
3. Profitability & Quality AVDL
Gross Margin N/A 94.9%
Operating Margin -2020.0% 2.5%
Net Profit Margin 0.0% -0.1%
Return on Equity (ROE) -80.8% -0.3%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) -$76M EBITDA $2.7M EBITDA
Cash Flow Margin N/A 1.1% EBITDA Mgn
Net Cash / Leverage $7.51 Book/Sh · -80.8% ROE $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 2.4% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GBIO (2) vs AVDL (7)
Institutional Metric GBIO AVDL Criterion Row Edge
Market Capitalization
Scale
$38.7M $2.1B Larger Scale AVDL
Trailing P/E Ratio
Valuation
7.9x 16.8x Lower Multiple GBIO
Forward P/E Ratio
Valuation
7.9x 28.8x Lower Multiple GBIO
Revenue Growth (YoY)
Growth
-78.9% +54.9% Higher Growth AVDL
Operating Margin (TTM)
Profitability
-2020.0% 2.5% Higher Margin AVDL
Net Profit Margin
Profitability
0.0% -0.1% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-80.8% -0.3% Higher ROE AVDL
52-Week Range Position
Momentum
62% ($0–$8) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.80β · 26% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
58.8 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$15M $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.5x EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$76M EBITDA ($7.51 Book/Sh · -80.8% ROE) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVDL +3.26 pp
GBIO: -2.38% · AVDL: +0.88%
3M Horizon AVDL +11.51 pp
GBIO: +2.89% · AVDL: +14.4%
6M Horizon AVDL +41.58 pp
GBIO: +28.67% · AVDL: +70.25%
1Y Horizon AVDL +162.32 pp
GBIO: -23.71% · AVDL: +138.61%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GBIO vs AVDL. Trailing 12-month operating profitability (GBIO -2020.0% vs AVDL 2.5%) and valuation multiples (GBIO 7.9x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

GBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15M
Gross MarginN/A
Op. Margin-2020.0%
ROE / Fwd P/E-80.8% · 7.9x
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $38.7M market capitalization and -2020.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GBIO vs AVDL Key Questions & Quantitative Answers

As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GBIO carries a Unified Composite Score of 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Technically, GBIO sits in a Neutral phase (RSI 39.7, UNCLASSIFIED options structure) and AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure).

AVDL leads the Growth & Scale pillar: GBIO posts -78.9% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (N/A gross margin, -2020.0% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, GBIO generates $15M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, GBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

GBIO screens cheaper on headline valuation multiples. GBIO trades at 7.9x Forward P/E, 7.9x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported EBITDA margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GBIO (-80.8% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, GBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 26% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 11, 2026. For educational research only; not investment advice.